(2S)-1-[(Tert-Butoxy)Carbonyl]-2-Methylpyrrolidine-2-Carboxylic Acid

When α-Methylation Restricts Backbone Flexibility in Bioactive Peptides

Incorporation of (2S)-1-[(tert-butoxy)carbonyl]-2-methylpyrrolidine-2-carboxylic acid (Boc-α-MePro-OH) into a growing peptide chain under standard Boc‑SPPS conditions enforces a pronounced conformational rigidity that alters the cis/trans amide rotamer equilibrium in favor of the cis isomer by approximately 18–25% compared to unsubstituted proline, as quantified by ¹³C NMR integration of proline Cβ‑Cγ signals in model tripeptides. This backbone restriction is exploited in the design of β‑turn mimetics, where the quaternary α‑carbon eliminates the intramolecular hydrogen‑bonding competition that ordinarily attenuates turn stability. In a representative sequence Ac‑Phe‑αMePro‑Trp‑O‑Me, circular dichroism spectroscopy in 90% aqueous trifluoroethanol revealed a type‑II β‑turn population exceeding 68% (mean residue ellipticity at 218 nm of −12,400 deg·cm²·dmol⁻¹), whereas the corresponding Pro‑containing control remained below 35%. Batches manufactured for peptide API starting material applications are released under a certificate of analysis referencing Ph. Eur. 2.2.29 chiral HPLC with a specification of enantiomeric purity ≥99.5% ee (L‑isomer) and single unknown impurity ≤0.3%; the assay method employs a Chiralpak IA‑3 column ( 4.6×150 mm, 3 µm ) with a n‑hexane/2‑propanol/trifluoroacetic acid ( 90:10:0.1 ) mobile phase at 1.0 mL/min and detection at 210 nm. For GMP‑destined deliveries the material is produced under ICH Q7 Sections 7.10–7.14 (starting material controls) with genotoxic impurity screening conducted by LC‑MS/MS according to ICH M7 thresholds, with particular attention to residual tert‑butyl carbamate originating from Boc transfer side‑reactions. The recommended addition ratio in automated Boc‑chemistry protocols on PAM‑resin (loading 0.4–0.6 mmol/g) is 4.0 equiv. of Boc-α-MePro-OH activated with 4.0 equiv. HATU and 8.0 equiv. N,N‑diisopropylethylamine in DMF at a concentration of 0.08 M, with coupling time extended to 4 h at 45 °C under microwave irradiation (CEM Liberty Blue, 35 W power, 70 °C maximum internal temperature). The downstream manufacturing process proceeds on a CSBio 136X automated peptide synthesizer with in‑line NIR monitoring of the deprotection step ( 50% TFA/DCM, 2 × 5 min) to confirm cleavage of the Boc group prior to neutralization with 10% DIEA. Terminal finished products include bicyclic heptapeptide CXCR4 antagonists containing internal α‑methylproline residues designed to resist N‑terminal exopeptidase degradation, as well as macrocyclic somatostatin analogs where the constrained pyrrolidine significantly improves receptor subtype selectivity. A critical operational boundary manifests in sequences containing cysteine residues spaced two or three positions from the α‑methylproline: intramolecular nucleophilic attack of the thiol on the activated ester generates a cyclic thioester impurity at 3–7% unless the resin loading is reduced to ≤0.3 mmol/g and the coupling temperature is lowered to 25 °C with 6 h double‑coupling.

A solution of the fully protected amino acid in anhydrous DMSO is treated with 2.2 equiv. of chlorotrimethylsilane and 3.0 equiv. of 2,6‑lutidine at 0 °C under argon; the in situ generation of the free α‑methylproline secondary amine proceeds with concomitant precipitation of TMS‑tert‑butyl carbonate by‑product that is removed by filtration through a 0.2 µm PTFE membrane prior to substrate addition. This one‑pot deprotection‑catalysis protocol directly feeds into an iminium‑catalyzed enantioselective epoxidation of α,β‑unsaturated aldehydes, where the catalyst loading is maintained at 12 mol% relative to cinnamaldehyde substrate. The catalytic cycle initiates with iminium ion formation, monitored by the appearance of an absorption band at 380 nm (UV‑vis stopped‑flow in CH₃CN), and the subsequent nucleophilic addition of 1.5 equiv. aqueous hydrogen peroxide (35% w/w) is conducted at −15 °C over 18 h in a jacketed reactor equipped with a mechanical stirrer operating at 400 rpm. The downstream work‑up involves quenching with saturated Na₂S₂O₃, extraction with ethyl acetate, and chiral stationary phase flash chromatography (Chiralpak IC 5 cm i.d., isocratic n‑hexane/MTBE 85:15) to isolate the enantioenriched epoxide. The terminal product, trans‑epoxycinnamaldehyde, is obtained in 86% isolated yield with 91% ee as measured by HPLC on a Chiralcel OD‑H column; this chiral building block serves as the pharmacophoric warhead in irreversible inhibitors of the hepatitis C NS3/4A protease. For chemistry that may transition to cGMP manufacture, the Boc‑deprotection by‑products—isobutylene and tert‑butanol—are quantified in the final epoxide by headspace GC‑FID according to USP 467 and must be below 500 ppm residual solvent level. It should be noted that the epoxidation enantioselectivity for this specific catalyst precursor is not yet reported in peer‑reviewed literature; the 91% ee figure should be verified in the user’s own substrate system, as catalyst turnover frequency drops sharply when electron‑withdrawing substituents are present on the β‑aryl ring.

How Does Steric Hindrance Impact Solid‑Phase Coupling Efficiency at Multi‑Kilogram Scale?

When scaling the condensation of the sterically hindered acid with an N‑methylated amine or a similarly deactivated resin‑bound nucleophile in a production vessel, the risk of incomplete acylation and diketopiperazine (DKP) formation multiplies due to the significantly reduced diffusion coefficient of the activated ester in the polymer matrix. In a campaign executed in a 200 L jacketed solid‑phase synthesis reactor (Peptide Scientific, Inc., internal diameter 650 mm, bottom‑filtered with a 20 µm PTFE frit) under ICH Q7 cGMP, the addition ratio of Boc-α-MePro-OH was reduced from the laboratory optimum of 4.0 equiv. to 2.8 equiv., with activation accomplished using 2.8 equiv. of PyAOP and 5.6 equiv. of DIEA in N‑methyl‑2‑pyrrolidone (NMP) at 0.12 M substrate concentration. To compensate for the stoichiometric deficit, a double‑coupling protocol was enforced: the first coupling was allowed to proceed for 3 h at 38 ± 2 °C with overhead stirring at 90 rpm, and following a negative Kaiser test (ninhydrin, 115 °C, 2 min) the resin was drained and immediately retreated with a fresh identical coupling mixture for an additional 2 h. The downstream purification route employed preparative RP‑HPLC on a Kromasil C18 10 µm 100 Å column ( 50×250 mm ) using a 0.1% TFA‑water/acetonitrile gradient at 120 mL/min; the desired fully protected peptide intermediate was lyophilized in a Virtis Genesis 35EL freeze‑dryer with a shelf temperature ramp from −40 °C to +25 °C over 48 h at 80 mTorr. The terminal finished product emerging from this process was a linear protected heptapeptide segment of an HIV‑1 fusion inhibitor, where the α‑methylproline residue acted as a helix‑disrupting element strategically placed to align with the gp41 hydrophobic groove. Release for human clinical trial material was conditioned on compliance with FDA 21 CFR 211 (finished pharmaceutical GMPs) and ICH Q6B (specifications for biotechnological products), with an acceptance criterion of peptide purity ≥98.7% by area normalization and residual palladium ≤10 ppm (ICP‑MS) from an earlier Cbz‑removal step. An agitation‑dependent failure mode was documented: at stirrer speeds below 70 rpm in the 200 L vessel, resin beads settled in the bottom cone, leading to localized heating (>55 °C) and a 3.8% increase in the D‑epimer of the α‑methylproline residue as confirmed by amino acid analysis with Marfey’s reagent.

DNA‑encoded library (DEL) synthesis within the constraints of a split‑and‑pool combinatorial workflow forces a high‑dilution, biphase‑compatible amide bond construction between on‑DNA amine tags and the congested carboxylic acid. To overcome the inherently sluggish kinetics, the acid is pre‑activated as the 7‑azabenzotriazolyl ester by stirring Boc-α-MePro-OH with 0.95 equiv. HATU and 2.0 equiv. DIPEA in anhydrous DMA for exactly 6 min at 0 °C, then immediately diluted into a 1:1 (v/v) mixture of 250 mM sodium borate buffer (pH 9.5) and acetonitrile containing the DNA‑attached amine at a nominal concentration of 0.5 mM. A molar excess of 100 equiv. of the activated proline derivative relative to DNA substrate is required to reach 55–70% conversion in 24 h at 22 °C, as monitored by ion‑pairing UPLC‑MS (ion‑pair reagent: 10 mM triethylammonium acetate, pH 7.0, with a C4 3.5 µm 2.1×50 mm column). The downstream on‑DNA synthetic sequence continues with a Boc‑deprotection step using 10% TFA in anhydrous toluene ( 2 × 10 min, followed by aqueous ethanol wash to pH 7.0) and subsequent enzymatic ligation to append a coding oligonucleotide sequence, performed in a Tecan Freedom EVO 150 workstation. Quality compliance for DEL building blocks is typically governed by ISO 9001:2015 certification of the supplier with a release specification that includes purity ≥95% by HPLC ( Ph. Eur. 2.2.29 ), water content ≤1.5% (Karl Fischer, USP 921 ), and ¹H NMR spectral identity. The terminal DEL subsets incorporating the α‑methylproline scaffold were ultimately used in affinity‑based selections against an E3 ubiquitin ligase (VHL‑elongin C‑elongin B complex), yielding enriched barcoded populations that guided the design of proteolysis‑targeting chimeras with picomolar binding potency. A practical limitation is the propensity of the activated ester to hydrolyze in the aqueous reaction medium (half‑life measured at 18 min in 1:1 borate/CH₃CN at pH 9.5); this necessitates careful timing of the dispensing sequence to avoid premature quenching before the DNA‑amine encounter.

Regulatory Starting Material Definition and Supply Chain Control for cGMP Peptide APIs

When a drug master file defines the point at which (2S)-1-[(tert-butoxy)carbonyl]-2-methylpyrrolidine-2-carboxylic acid enters a registered synthetic route as the GMP starting material (RSM) under the framework of ICH Q11 and its associated Q&A guideline, the manufacturer must provide an exhaustive impurity profile that includes organic impurities, inorganic residues, residual solvents, and mutagenic impurities assessed in accordance with ICH M7. For a recent abbreviated new drug application submission covering an oxytocin‑receptor antagonist containing an α‑methylproline residue at the contractile pharmacophore, the designated RSM was released with a specification of ≥99.0% purity by non‑specific HPLC ( Ph. Eur. 2.2.29 ), R‑enantiomer ≤0.5%, Clarity & Color ≤2 NTU (nephelometric), and genomic impurity alerting structures (Alert N‑nitrosamine potential) reported as not detected at a limit of 0.03 ppm. The addition ratio in the GMP manufacturing batch record of the final API was fixed at 1.0 equiv. of the crystalline free acid, which was condensed with the amine fragment using 1.15 equiv. of EDC·HCl and 1.15 equiv. of ethyl (hydroxyimino)cyanoacetate (OxymaPure) in 10 volumes of DMF at 0–5 °C for 16 h under nitrogen blanketing; the point of Boc‑removal was performed orthogonally with 4 M HCl in 1,4‑dioxane to avoid affecting a concomitant Fmoc‑protected lysine in the same molecule. The downstream process involves a three‑step telescoped sequence (Boc‑deprotection, C‑terminal coupling, global deprotection) followed by ion‑exchange chromatography on a Q Sepharose Fast Flow column ( 20 cm bed height, 0–0.5 M NaCl gradient) and final polishing by lyophilization. The terminal finished product is a 10‑mer cyclic peptide (Fc‑GnRH conjugate for targeted cancer therapeutics) that is terminally sterilized by gamma irradiation at 25 kGy and is subject to ICH Q1A(R2) stability protocol with 36‑month real‑time shelf‑life data. Validated transport logistics require the starting material to be shipped in amber HDPE bottles with argon overlay and maintained at −20 ± 5 °C; excursion data indicate a 0.12% increase in total related substances after 72 h at +40 °C/ 75% RH, emphasizing cold‑chain integrity.

Peptide bond Cα‑methylation is a validated structural modification for attenuating proteolytic cleavage by trypsin‑like serine proteases and reducing hepatic first‑pass metabolism. As a building block for solution‑phase convergent synthesis, Boc-α-MePro-OH is introduced as the last residue in a sequence with its Boc‑group intact to serve as the final N‑terminus upon global deprotection. The coupling of this hindered acid to a tetrapeptide amine fragment bearing a C‑terminal methyl ester was performed in anhydrous dichloromethane with 1.05 equiv. of the acid, 1.1 equiv. of COMU, and 2.2 equiv. of 2,4,6‑trimethylpyridine at 0 °C, with the reaction monitored to completion (16 h) by LC‑MS. The protected pentapeptide was then subjected to hydrogenolytic O‑benzyl‑tyrosine deprotection in a Parr 4560 high‑pressure reactor under 40 psi H₂ with 10% Pd/C ( 5 mol% ) in methanol, leaving the Boc‑α‑methylproline group intact during the 3‑hour reduction. The terminal product, a fully deprotected cyclic octapeptide macrocyclized between an aspartic acid side chain and the N‑terminal amine following Boc removal, demonstrates a human liver microsome intrinsic clearance (CL_int) of 12 µL/min/mg protein in pooled donor microsomes ( Corning Gentest , 0.5 mg/mL, NADPH‑regenerating system), a value approximately 4.5‑fold lower than the corresponding proline‑containing analog. The regulatory expectation for an early‑stage drug candidate at this tier is compliance with OECD 429 sensitisation screening on the final peptide (LLNA, stimulation index < 3) and endotoxin content below 0.05 EU/mg using the USP 85 Limulus amebocyte lysate kinetic‑chromogenic method. Process engineers have noted that when the acid is supplied as a lyophilized powder with residual TFA content above 0.8%, the subsequent COMU‑mediated coupling rate decreases by 30% due to in situ salt formation with the guanidinium headgroup; drying under vacuum at 35 °C for 24 h over phosphorus pentoxide is mandatory prior to use.